| ［1］ |
Zhang C, Xiao C, Dang E, et al. CD100⁃plexin⁃B2 promotes the inflammation in psoriasis by activating NF⁃κB and the inflammasome in keratinocytes［J］. J Invest Dermatol, 2018,138（2）:375⁃383. doi: 10.1016/j.jid.2017.09.005.
|
| ［2］ |
Yan S, Xu Z, Lou F, et al. NF⁃κB⁃induced microRNA⁃31 promotes epidermal hyperplasia by repressing protein phosphatase 6 in psoriasis［J］. Nat Commun, 2015,6:7652. doi: 10.1038/ncomms8652.
|
| ［3］ |
Müller A, Hennig A, Lorscheid S, et al. IκBζ is a key transcriptional regulator of IL⁃36⁃driven psoriasis⁃related gene expression in keratinocytes［J］. Proc Natl Acad Sci U S A, 2018,115（40）:10088⁃10093. doi: 10.1073/pnas.1801377115.
|
| ［4］ |
Ba W, Xu Y, Yin G, et al. Metformin inhibits pro⁃inflammatory responses via targeting nuclear factor⁃κB in HaCaT cells［J］. Cell Biochem Funct, 2019,37（1）:4⁃10. doi: 10.1002/cbf.3367.
|
| ［5］ |
Glossmann H, Reider N. A marriage of two "Methusalem" drugs for the treatment of psoriasis?: arguments for a pilot trial with metformin as add⁃on for methotrexate［J］. Dermatoendocrinol, 2013,5（2）:252⁃263. doi: 10.4161/derm.23874.
|
| ［6］ |
Buerger C. Epidermal mTORC1 signaling contributes to the pathogenesis of psoriasis and could serve as a therapeutic target［J］. Front Immunol, 2018,9:2786. doi: 10.3389/fimmu. 2018. 02786.
|
| ［7］ |
Bürger C, Shirsath N, Lang V, et al. Blocking mTOR signalling with rapamycin ameliorates imiquimod⁃induced psoriasis in mice［J］. Acta Derm Venereol, 2017,97（9）:1087⁃1094. doi: 10. 2340/00015555⁃2724.
|
| ［8］ |
Varshney P, Saini N. PI3K/AKT/mTOR activation and autophagy inhibition plays a key role in increased cholesterol during IL⁃17A mediated inflammatory response in psoriasis［J］. Biochim Biophys Acta Mol Basis Dis, 2018,1864（5 Pt A）:1795⁃1803. doi: 10.1016/j.bbadis.2018.02.003.
|
| ［9］ |
Gargalionis AN, Malakou LS, Adamopoulos C, et al. Polycystin⁃1 downregulation induces ERK⁃dependent mTOR pathway activation in a cellular model of psoriasis［J］. Biochim Biophys Acta Mol Basis Dis, 2018,1864（10）:3468⁃3476. doi: 10.1016/j.bbadis.2018.07.036.
|
| ［10］ |
Liu Y, Yang F, Ma W, et al. Metformin inhibits proliferation and proinflammatory cytokines of human keratinocytes in vitro via mTOR⁃signaling pathway［J］. Pharm Biol, 2016,54（7）:1173⁃1178. doi: 10.3109/13880209.2015.1057652.
|
| ［11］ |
Yang Q, Liu X, Liu Q, et al. Roles of mTORC1 and mTORC2 in controlling γδ T1 and γδ T17 differentiation and function［J］. Cell Death Differ, 2020,27（7）:2248⁃2262. doi: 10.1038/s41418⁃020⁃0500⁃9.
|
| ［12］ |
Kim YC, Guan KL. mTOR: a pharmacologic target for autophagy regulation［J］. J Clin Invest, 2015,125（1）:25⁃32. doi: 10.1172/JCI73939.
|
| ［13］ |
Balato A, Lembo S, Ayala F, et al. Mechanistic target of rapamycin complex 1 is involved in psoriasis and regulated by anti⁃TNF⁃α treatment［J］. Exp Dermatol, 2017,26（4）:325⁃327. doi: 10.1111/exd.13267.
|
| ［14］ |
Buerger C, Shirsath N, Lang V, et al. Inflammation dependent mTORC1 signaling interferes with the switch from keratinocyte proliferation to differentiation［J/OL］. PLoS One, 2017,12（7）:e0180853. doi: 10.1371/journal.pone.0180853.
|
| ［15］ |
Wu J, Xiao S, Ren J, et al. A unified mitochondria mechanistic target of rapamycin acyl⁃coenzyme A dehydrogenase 10 signal relay modulation for metformin growth inhibition in human immortalized keratinocytes cells［J/OL］. J Cell Biochem, 2018. （2018⁃11⁃11）［2020⁃09⁃16］. https://pubmed.ncbi.nlm.nih.gov/30206977/. doi:10.1002/jcb.27481.
|
| ［16］ |
Wu Y, Liu L, Bian C, et al. MicroRNA let⁃7b inhibits keratinocyte differentiation by targeting IL⁃6 mediated ERK signaling in psoriasis［J］. Cell Commun Signal, 2018,16（1）:58. doi: 10.1186/s12964⁃018⁃0271⁃9.
|
| ［17］ |
Li W, Ma W, Zhong H, et al. Metformin inhibits proliferation of human keratinocytes through a mechanism associated with activation of the MAPK signaling pathway［J］. Exp Ther Med, 2014,7（2）:389⁃392. doi: 10.3892/etm.2013.1416.
|
| ［18］ |
Wang X, Li R, Zhao X, et al. Metformin promotes HaCaT cell apoptosis through generation of reactive oxygen species via Raf⁃1⁃ERK1/2⁃Nrf2 inactivation［J］. Inflammation, 2018,41（3）:948⁃958. doi: 10.1007/s10753⁃018⁃0749⁃z.
|
| ［19］ |
Kvist⁃Hansen A, Hansen PR, Skov L. Systemic treatment of psoriasis with JAK inhibitors: a review［J］. Dermatol Ther （Heidelb）, 2020,10（1）:29⁃42. doi: 10.1007/s13555⁃019⁃00347⁃w.
|
| ［20］ |
Nogueira M, Puig L, Torres T. JAK inhibitors for treatment of psoriasis: focus on selective TYK2 inhibitors［J］. Drugs, 2020,80（4）:341⁃352. doi: 10.1007/s40265⁃020⁃01261⁃8.
|
| ［21］ |
Andrés RM, Hald A, Johansen C, et al. Studies of Jak/STAT3 expression and signalling in psoriasis identifies STAT3⁃Ser727 phosphorylation as a modulator of transcriptional activity［J］. Exp Dermatol, 2013,22（5）:323⁃328. doi: 10.1111/exd.12128.
|
| ［22］ |
Clarysse K, Pfaff CM, Marquardt Y, et al. JAK1/3 inhibition preserves epidermal morphology in full⁃thickness 3D skin models of atopic dermatitis and psoriasis［J］. J Eur Acad Dermatol Venereol, 2019,33（2）:367⁃375. doi: 10.1111/jdv.15301.
|
| ［23］ |
Calautti E, Avalle L, Poli V. Psoriasis: a STAT3⁃centric view［J］. Int J Mol Sci, 2018,19（1）: 171⁃185. doi: 10.3390/ijms19010171.
|
| ［24］ |
苏蓓蓓, 甘泉, 甘才斌. 二甲双胍对银屑病样小鼠模型皮损炎症状态及磷酸化Stat3蛋白表达的影响［J］. 中华皮肤科杂志, 2019,52（7）:475⁃480. doi: 10.3760/cma.j.issn.0412⁃4030.2019. 07.006.
|
| ［25］ |
Tsuji G, Hashimoto⁃Hachiya A, Yen VH, et al. Metformin inhibits IL⁃1β secretion via impairment of NLRP3 inflammasome in keratinocytes: implications for preventing the development of psoriasis［J］. Cell Death Discov, 2020,6:11. doi: 10.1038/s41420⁃020⁃0245⁃8.
|
| ［26］ |
Su YJ, Chen TH, Hsu CY, et al. Safety of metformin in psoriasis patients with diabetes mellitus: a 17⁃year population⁃based real⁃world cohort study［J］. J Clin Endocrinol Metab, 2019,104（8）:3279⁃3286. doi: 10.1210/jc.2018⁃02526.
|
| ［27］ |
Wu CY, Shieh JJ, Shen JL, et al. Association between antidiabetic drugs and psoriasis risk in diabetic patients: results from a nationwide nested case⁃control study in Taiwan［J］. J Am Acad Dermatol, 2015,72（1）:123⁃130. doi: 10.1016/j.jaad.2014. 08.042.
|
| ［28］ |
El⁃Gharabawy RM, Ahmed AS, Al⁃Najjar AH. Mechanism of action and effect of immune⁃modulating agents in the treatment of psoriasis［J］. Biomed Pharmacother, 2017,85:141⁃147. doi: 10.1016/j.biopha.2016.11.105.
|
| ［29］ |
Singh S, Bhansali A. Randomized placebo control study of insulin sensitizers （metformin and pioglitazone） in psoriasis patients with metabolic syndrome （topical treatment cohort）［J］. BMC Dermatol, 2016,16（1）:12. doi: 10.1186/s12895⁃016⁃0049⁃y.
|
